Glutathione 600mg Review

Glutathione occupies a singular position in redox biology. As the most abundant intracellular low-molecular-weight thiol in mammalian tissues, it participates in antioxidant defense, xenobiotic metabolism, immune signaling, and the maintenance of protein thiol homeostasis across virtually every cell type studied. ^[1] Unlike many peptide research compounds that emerged from targeted drug discovery programs, glutathione is an endogenous tripeptide that has been studied continuously since its initial isolation by Hopkins in 1921. That depth of background literature makes it simultaneously one of the most tractable and one of the most technically nuanced compounds a researcher can work with.

The Apollo Peptide Sciences 600 mg vial represents a high-mass research format that is well suited to cell culture depletion-restoration models, tissue bath experiments, and multi-arm pharmacological studies where milligram-scale quantities are consumed rapidly. This review synthesizes the available peer-reviewed literature on exogenous glutathione administration, evaluates the pharmacokinetic and mechanistic data, and provides practical guidance on reconstitution, verification, and study design for researchers sourcing this compound.

Editor's Verdict

Glutathione at 600 mg per vial is among the more versatile research peptide formats available for longevity and redox biology studies. At $35.00 the cost per milligram is competitive, and the lyophilized powder format preserves reduced glutathione (GSH) stability far better than pre-dissolved liquid preparations, which are prone to rapid oxidation to the disulfide form (GSSG). ^[2]

The scientific case for studying exogenous glutathione in preclinical models is robust. Decades of depletion studies using buthionine sulfoximine (BSO) and N-acetylcysteine (NAC) supplementation paradigms have established clear causal links between cellular GSH levels and oxidative-stress-related pathology. ^[3] More recent work on liposomal and S-acetyl delivery forms has reignited interest in systemic bioavailability, though the evidence base for reduced glutathione itself remains mechanistically grounded rather than pharmacokinetically simple. ^[4]

For researchers focused on longevity endpoints, cognitive tissue protection, or mitochondrial redox balance, this 600 mg vial offers enough material for a well-powered multi-group rodent study or an extended in-vitro program without the per-experiment cost concerns that accompany smaller formats.

Specifications

The 600 mg vial format is notably generous compared to many research peptide offerings, where 1-10 mg vials are standard for more complex or synthetic sequences. Because glutathione is a naturally occurring tripeptide amenable to scalable biosynthetic production or large-scale chemical synthesis, higher vial masses are achievable without proportional cost increases. This makes the Apollo Peptide Sciences offering particularly attractive for researchers who consume milligram quantities per experimental run.

Purity at ≥98% by HPLC is the minimum acceptable specification for mechanistic research. For studies where stoichiometric precision matters, such as GSH:GSSG ratio experiments or enzyme kinetics with glutathione peroxidase (GPx) or glutathione S-transferase (GST), researchers should verify that the stated purity reflects reduced GSH and not total glutathione (GSH plus GSSG combined). See the Purity and Verification section for guidance on interpreting the CoA correctly.

What It Is: Chemistry, Origin, and Sequence Detail

Glutathione is classified as a tripeptide, but its chemistry contains an unusual structural feature that distinguishes it from standard ribosomal peptides. The peptide bond between glutamate and cysteine is formed at the gamma-carboxyl group of glutamate rather than the alpha-carboxyl group that participates in standard peptide bonds. ^[1] This gamma-peptide linkage is the reason glutathione is resistant to hydrolysis by most extracellular peptidases and proteases, because the majority of these enzymes recognize and cleave alpha-peptide bonds. The biological significance of this resistance is substantial: it means free glutathione circulating in plasma or present in extracellular fluids retains its thiol functionality rather than being rapidly degraded. Intracellularly, GSH catabolism proceeds through the gamma-glutamyl cycle, initiated by gamma-glutamyltranspeptidase (GGT) on the outer leaflet of certain cell membranes. ^[5]

The linear sequence, conventionally written gamma-L-glutamyl-L-cysteinyl-glycine, encodes three critical functional groups. The glutamate residue provides a free alpha-amino group and participates in gamma-glutamyl transfer reactions. The cysteine residue carries the thiol (-SH) group that defines the reducing capacity of GSH; this is the nucleophilic site that reacts with electrophilic xenobiotics, reduces hydrogen peroxide and lipid hydroperoxides (with GPx), and maintains protein cysteine residues in their reduced state. ^[6] The glycine residue at the C-terminus carries a free carboxyl group and provides a degree of conformational flexibility. The overall pKa of the cysteine thiol in glutathione is approximately 9.2, meaning that at physiological pH around 7.4, the thiol exists predominantly in the protonated -SH form, though the reactive thiolate anion (-S-) is present at low but kinetically relevant concentrations.

The reduced form (GSH) is distinguished from the oxidized disulfide form (GSSG) by the availability of the free thiol. In healthy cells, the GSH:GSSG ratio is typically maintained above 100:1, reflecting continuous regeneration of GSH from GSSG by glutathione reductase (GR) in an NADPH-dependent reaction. ^[7] The research compound sold by Apollo Peptide Sciences is specifically the reduced form (CAS 70-18-8), which is the biologically active antioxidant species. Oxidized glutathione (GSSG, CAS 27025-41-8) is a separate compound with distinct pharmacology and is not what is supplied in this 600 mg vial.

The biosynthetic route in mammalian cells proceeds in two ATP-dependent steps catalyzed by gamma-glutamylcysteine synthetase (GCS, also called glutamate-cysteine ligase, GCL) and glutathione synthetase (GSS). GCL is the rate-limiting enzyme and is subject to feedback inhibition by GSH itself, creating an autoregulatory loop. ^[8] The availability of cysteine is considered the primary substrate-level determinant of intracellular GSH synthesis, which is the mechanistic rationale for N-acetylcysteine as an indirect GSH-raising strategy in many research paradigms.

Molecular weight of 307.32 g/mol means that a 600 mg vial contains approximately 1.95 mmol of compound, a quantity sufficient to prepare hundreds of independent micromolar-range solutions for cell culture work. For in-vivo rodent studies using literature-reported research doses in the range of 100-500 mg/kg body weight (as used in oxidative stress depletion models), a 600 mg vial provides material for several individual animal experiments or a complete small pilot study.

Mechanism of Action

Primary Antioxidant Functions

Glutathione's antioxidant activity operates through multiple distinct biochemical pathways, each with its own kinetics, enzyme partners, and subcellular localization. The best-characterized pathway is the reduction of hydrogen peroxide (H2O2) and organic hydroperoxides (ROOH) by glutathione peroxidase enzymes (GPx1-8). ^[6] In this reaction, two molecules of GSH donate electrons to reduce H2O2 to water or ROOH to the corresponding alcohol, generating GSSG as the oxidized product. GPx1 is primarily cytosolic and mitochondrial, GPx4 is unique in its ability to reduce phospholipid hydroperoxides directly within membrane bilayers, making it the central enzymatic defense against ferroptotic cell death. ^[9] The regeneration of GSH from GSSG by glutathione reductase (GR) completes the cycle and is driven by NADPH derived from the pentose phosphate pathway, linking redox homeostasis to central carbon metabolism.

A second major antioxidant pathway involves direct non-enzymatic reaction of GSH with free radical species, including hydroxyl radicals (HO-), superoxide (O2-), and lipid peroxyl radicals (LOO-). While rate constants for these reactions are generally lower than enzyme-catalyzed pathways, the very high intracellular GSH concentration (typically 1-10 mM in most cell types) ensures that mass-action kinetics allow substantial scavenging capacity. ^[1]

Glutaredoxins (Grx1 and Grx2) use GSH as a reductant to catalyze the reduction of protein mixed disulfides (protein-S-SG, a modification called S-glutathionylation). This reversible post-translational modification of cysteine residues can both protect proteins from irreversible oxidation during oxidative stress and function as a regulatory signal modulating enzyme activity, transcription factor binding, and cytoskeletal organization. ^[10] The deglutathionylation reaction by Grx restores the protein thiol and generates GSSG. This cycle of S-glutathionylation and deglutathionylation is increasingly recognized as a redox signaling mechanism rather than simply a damage response.

Xenobiotic Conjugation and Phase II Metabolism

The glutathione S-transferase (GST) superfamily catalyzes the conjugation of GSH to electrophilic substrates, a key Phase II detoxification reaction. ^[5] Substrates include reactive metabolites generated by cytochrome P450 oxidation, environmental electrophiles such as acrolein and 4-hydroxynonenal (4-HNE, a product of lipid peroxidation), heavy metals, and reactive oxygen species. The resulting glutathione conjugates (GS-X) are typically more polar and water-soluble than the parent compound and are exported from cells by ATP-binding cassette transporters, notably multidrug resistance-associated protein 1 (MRP1/ABCC1) and MRP2 (ABCC2). ^[11] In the kidney tubule, GS-X conjugates are processed through the mercapturic acid pathway, yielding N-acetylcysteine conjugates excreted in urine. This entire pathway has direct relevance to preclinical toxicology models where GSH availability influences the hepatotoxicity and nephrotoxicity of reactive drug metabolites.

Mitochondrial Glutathione Pool

Mitochondria cannot synthesize GSH de novo and must import it from the cytosol against a concentration gradient via two identified carriers in the inner mitochondrial membrane: the dicarboxylate carrier (DIC) and the oxoglutarate carrier (OGC). ^[7] The mitochondrial GSH pool (mGSH) represents roughly 10-15% of total cellular GSH and is critical for scavenging mitochondrial H2O2 produced by the electron transport chain. Depletion of mGSH specifically (achievable experimentally with 3-hydroxy-2-norvaline or ethacrynic acid in some models) induces mitochondrial permeability transition and triggers apoptotic and necrotic cell death pathways at concentrations that spare cytosolic GSH. This mechanistic compartmentalization means that researchers studying mitochondrial function need to consider not just total cellular GSH content but the specific status of the mitochondrial pool, which may respond differently to exogenous GSH supplementation.

Nuclear Functions and Transcriptional Regulation

Nuclear GSH levels regulate the redox state of key transcription factors including NF-kB, AP-1, and Nrf2 through effects on DNA-binding domain cysteine residues. ^[8] The Nrf2-KEAP1 pathway is particularly well-studied: under baseline conditions, KEAP1 (Kelch-like ECH-associated protein 1) contains reactive cysteine residues (Cys273, Cys288, Cys151) that, when modified by electrophiles or under oxidative conditions, release Nrf2 for nuclear translocation. Nrf2 then drives transcription of antioxidant response element (ARE)-containing genes, including those encoding GCL subunits, GST isoforms, heme oxygenase-1 (HO-1), and thioredoxin reductase. This creates a feedforward loop where initial GSH depletion leads to Nrf2 activation and subsequent upregulation of GSH biosynthetic capacity. The degree to which exogenous GSH supplementation modulates Nrf2 activity independently of KEAP1-reactive electrophile sensing is an active area of research with contested findings.

Tissue Distribution of Endogenous Glutathione

Endogenous GSH is present at varying concentrations across tissues, reflecting differences in synthesis capacity, turnover rate, and metabolic demand. The liver is the richest source, with intracellular concentrations of 5-10 mM. ^[1] The liver also plays a central role in supplying cysteine to peripheral tissues through the gamma-glutamyl cycle and in releasing GSH into bile (where it reaches millimolar concentrations) and plasma (where it is present at much lower micromolar concentrations, 3-7 micromolar in human plasma). The lung, kidney, and intestinal epithelium maintain high GSH concentrations as frontline barriers to inhaled and ingested oxidants. Erythrocytes maintain GSH at 2-3 mM to protect hemoglobin from oxidative denaturation. The brain has a more complex picture: neurons have moderate GSH concentrations but are highly dependent on astrocyte-derived cysteine and cysteinylglycine for maintaining their GSH pools, creating an intercellular metabolic dependency that has significant implications for neurodegeneration research. ^[12]

What the Research Says

Study 1: Exogenous Glutathione and Oxidative Stress in Aging Rodent Models

One of the foundational preclinical observations supporting interest in exogenous GSH is the age-associated decline in tissue glutathione levels documented across multiple rodent studies. Sekhar and colleagues, working primarily with human data but grounded in earlier animal work, demonstrated that GSH synthesis rates decline significantly with aging, with older subjects showing reductions of 30-50% in muscle and plasma GSH compared to younger controls. ^[13] In rodent aging models, intraperitoneal administration of GSH has been used to probe whether restoring depleted pools reverses age-associated oxidative markers. Studies in aged rats using literature-reported research doses of approximately 100-250 mg/kg have documented reductions in liver thiobarbituric acid-reactive substances (TBARS, a lipid peroxidation marker), improvements in mitochondrial membrane potential, and partial restoration of GPx and GR enzyme activities. ^[14] The limitations of these rodent studies include the non-physiological delivery route (intraperitoneal rather than oral), the relatively short intervention windows, and the challenge of attributing observed effects specifically to exogenous GSH rather than to GSH precursor recycling following catabolism.

The experimental design typically employed in this literature involves baseline measurement of GSH and GSSG in target tissues using the recycling assay (Tietze method) or HPLC with fluorescent derivatization, followed by treatment and comparison against vehicle-treated age-matched controls. Researchers planning similar studies with the Apollo Peptide Sciences 600 mg vial should note that the most reproducible endpoint is tissue GSH measured by HPLC rather than the less specific colorimetric DTNB (Ellman's reagent) assay when high thiol backgrounds are anticipated.

Study 2: Intravenous Glutathione and Neurological Endpoints

Sechi and colleagues conducted an open-label clinical pilot study examining the effects of intravenous GSH on motor scores in Parkinson's disease patients, generating preclinical interest in the neuroprotective potential of systemic GSH delivery. ^[12] While that specific study used human subjects and cannot be applied to research framing, it motivated numerous subsequent rodent models using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic lesioning to test whether exogenous GSH protects nigrostriatal neurons. In MPTP-lesioned mice, pretreatment with intraperitoneal GSH at research doses of 150-300 mg/kg attenuated striatal dopamine depletion and reduced tyrosine hydroxylase-positive cell loss in the substantia nigra compared to vehicle controls. The proposed mechanism involves direct thiol exchange with MPTP-generated reactive species and maintenance of mitochondrial complex I activity, which is the primary target of MPTP toxicity. Limitations include the acute lesioning model not fully recapitulating the progressive nature of Parkinson's pathology, and the use of supraphysiological doses far exceeding what exogenous GSH administration could achieve through the blood-brain barrier under normal conditions. These constraints are important design considerations for researchers using this model.

Study 3: Glutathione Depletion Models and Ferroptosis Research

A rapidly growing application of glutathione research is the study of ferroptosis, an iron-dependent, non-apoptotic form of regulated cell death driven by lipid peroxidation. ^[9] The central gatekeeper of ferroptosis is GPx4, which requires GSH as its obligate reductant to reduce phospholipid hydroperoxides (PLOOHs). When cellular GSH is depleted (experimentally using BSO to inhibit GCL, or by using system Xc- inhibitors such as erastin or RSL3 to block cystine import), GPx4 activity collapses, PLOOHs accumulate, and ferroptotic cell death ensues. Rescue experiments in this literature standardly involve co-treatment with exogenous GSH, GSH esters, or N-acetylcysteine to demonstrate that ferroptosis induction was genuinely dependent on GSH depletion rather than off-target effects.

Dixon and colleagues' landmark 2012 Cell paper characterizing ferroptosis used GSH rescue as a key mechanistic control, establishing a methodological standard that has been replicated across hundreds of subsequent ferroptosis papers. ^[9] The quantitative threshold for ferroptosis triggering appears to be quite sensitive: reductions of GSH to approximately 20% of baseline are sufficient to induce GPx4 collapse in many cell lines, while restoration to 50-60% of baseline is sufficient for protection in most models. This threshold sensitivity means that the 600 mg vial format is well matched to experiments requiring precise, calibrated GSH addition across multiple concentration points in multi-well plate designs.

Researchers should note that the cell-impermeant nature of free GSH means that exogenous addition to culture media does not efficiently raise intracellular GSH in most cell types without extended incubation periods or the use of delivery vehicles. Cell-permeable forms including GSH monoethyl ester (GSH-MEE) or the S-acetyl form are frequently used in ferroptosis rescue experiments where rapid intracellular elevation is needed. This is a critical experimental design caveat when planning studies with reduced GSH, and our peptide reconstitution guide includes additional notes on solubility and stability for thiol-containing compounds.

Study 4: Oral Bioavailability and Systemic Distribution

The question of whether orally administered glutathione survives gastrointestinal transit and reaches systemic circulation as intact GSH has been controversial for decades. Earlier work by Witschi and colleagues using rats suggested that luminal GSH was extensively hydrolyzed by GGT on the brush border of intestinal epithelial cells, releasing glutamate, cysteine, and glycine rather than intact GSH. ^[15] This hydrolysis was regarded as evidence that oral GSH primarily functions as a cysteine precursor for endogenous re-synthesis rather than as a direct systemic antioxidant. Subsequent studies using isotope-labeled GSH in humans and animals have partially revised this view: a study by Richie and colleagues found that supplementation with 250-1000 mg oral GSH per day over six months significantly increased erythrocyte GSH concentrations in human subjects, suggesting that either some intact absorption occurs or that the cysteine precursor hypothesis fully accounts for the observed elevation. ^[16]

The preclinical mechanistic question of intact versus hydrolysis-mediated absorption is well addressed by portal vein sampling experiments in rodents, where literature-reported research protocols have used cannulated rats to collect portal blood at timed intervals following intragastric GSH administration. These studies generally find that while plasma GSH concentration increases after oral dosing, the majority of the increase can be accounted for by cysteine-derived re-synthesis, with only minor contributions from intact tripeptide transport. The exception may be at supraphysiological doses where transepithelial passive permeability plays a greater role. This distinction matters for researchers designing bioavailability studies: intact-tripeptide tracking requires stable-isotope labeling (typically deuterium or 13C on the cysteine residue) to distinguish exogenous intact GSH from endogenously synthesized GSH in tissue samples.

Study 5: Mitochondrial Protection in Ischemia-Reperfusion Models

Cardiac and hepatic ischemia-reperfusion (I/R) injury models have generated substantial literature on the protective potential of GSH pre- or co-treatment. During ischemia, cellular GSH is progressively oxidized to GSSG and partially exported, so that reperfusion begins from a depleted GSH state that cannot adequately scavenge the burst of reactive oxygen species (ROS) generated by xanthine oxidase, mitochondrial complex I, and NADPH oxidase upon reoxygenation. ^[7] Borutaite and colleagues, among others, demonstrated in isolated perfused rat heart models that pre-perfusion with GSH at millimolar concentrations significantly reduced infarct size and preserved mitochondrial electron transport chain (ETC) activity compared to vehicle controls. The mechanistic interpretation centers on GSH's ability to maintain complex I iron-sulfur centers in the reduced state, preventing the superoxide burst from irreversible complex I inactivation during the reperfusion phase.

In hepatic I/R models, intravenous GSH administration in rodents has been shown to reduce plasma ALT and AST elevations, lower liver malondialdehyde (MDA) content, and partially preserve mitochondrial membrane potential compared to untreated I/R controls. Research doses in this literature range from 50 to 500 mg/kg administered as intravenous bolus or infusion in the immediate pre-ischemic or early reperfusion period. The 600 mg Apollo Peptide Sciences vial provides material for a full rodent dosing series across this range at typical mouse or rat body weights, making it practical for multi-arm I/R studies.

Pharmacokinetics

Understanding the pharmacokinetic profile of exogenous glutathione is essential for interpreting preclinical study outcomes and designing rational dosing intervals in animal models. The kinetics differ substantially by route of administration.

The extremely short plasma half-life of intact intravenously administered GSH (approximately 2-4 minutes in rodents) reflects rapid extraction by the liver and kidney, where GGT on sinusoidal and tubular cell surfaces initiates catabolism. ^[5] This kinetic reality means that single-bolus IV dosing in animal models produces a brief spike of circulating GSH followed by a sustained release of constituent amino acids, particularly cysteine, which can then be taken up by peripheral tissues for endogenous GSH re-synthesis. The net effect on tissue GSH at 24 hours post-dose may thus reflect a combination of direct uptake of intact GSH (in tissues reached during the initial distribution phase) and subsequent de novo synthesis.

Intraperitoneal delivery, the most common route in small animal research, provides a somewhat longer absorption window that partially buffers against the immediate first-pass extraction. Literature-reported research protocols in the I/R and aging literature typically use IP delivery at doses of 100-500 mg/kg, and tissue GSH measurements 30-120 minutes post-injection generally show 20-80% elevations in liver, kidney, and lung GSH compared to vehicle controls. ^[14]

Oral delivery presents the most pharmacokinetically complex picture, as discussed in the research section. For studies specifically examining the consequences of sustained GSH supplementation on steady-state tissue antioxidant capacity, repeated oral dosing over multiple weeks is the most consistent literature paradigm, with endpoints measured at the end of the treatment period rather than acutely. The dosage calculation guide on this site provides worked examples for converting published mg/kg research doses to preparation volumes for common rodent research protocols.

Blood-brain barrier (BBB) penetration of intact GSH is highly restricted under normal physiological conditions. The BBB lacks a known dedicated GSH transporter on the luminal surface of brain endothelial cells, though the abluminal (brain-facing) surface does express GGT and gamma-glutamyl transpeptidase activity that may facilitate cysteinylglycine and cysteine entry into the brain interstitium. ^[12] Under neuroinflammatory conditions or after BBB disruption (as in stroke or traumatic brain injury models), enhanced paracellular permeability may allow limited intact GSH access, which could partially explain the neuroprotective effects observed with systemic GSH administration in some animal models.

Purity and Verification

What a Certificate of Analysis Should Contain

For a compound as chemically labile as reduced glutathione, the Certificate of Analysis (CoA) is an especially critical quality document. A research-grade CoA from a reputable supplier should include at minimum: HPLC purity expressed as a percentage with stated column type, mobile phase, and UV detection wavelength (220 nm is standard for glutathione due to the amide chromophore, though 210 nm provides slightly better sensitivity); mass spectrometry confirmation of molecular weight (307.32 g/mol, monoisotopic 307.08 Da); and moisture content by Karl Fischer titration. ^[2]

HPLC purity for reduced glutathione must be interpreted carefully. If the CoA presents a single peak at the GSH retention time with purity ≥98%, but does not separately resolve and quantify GSSG, the stated purity may include oxidized glutathione eluting close to or co-eluting with GSH depending on the chromatographic method. The most rigorous methods use reversed-phase HPLC with UV or electrochemical detection following derivatization with reagents such as monobromobimane (mBrB) or 5-sulfosalicylic acid (SSA) deproteinization, which provide clear separation of GSH and GSSG peaks and accurate quantification of both species. Researchers should contact Apollo Peptide Sciences to confirm that the HPLC method used in their CoA resolves GSH from GSSG, or request an electrochemical detection profile if available.

Free Thiol Content Assay

An orthogonal and inexpensive verification step that can be performed in any laboratory with spectrophotometric capability is the Ellman's reagent assay (DTNB, 5,5-dithio-bis(2-nitrobenzoic acid)). Dissolving a known mass of the supplied powder in phosphate buffer and reacting with DTNB at pH 7.4 yields a yellow chromophore (2-nitro-5-thiobenzoic acid, TNB) detectable at 412 nm with a molar extinction coefficient of approximately 14,150 M-1 cm-1. Comparing measured thiol content to the theoretical value based on stated mass and molecular weight provides a rapid estimate of free thiol purity. A result within 5% of theoretical confirms that the free thiol is intact and that excessive GSSG contamination (which would reduce apparent thiol content) is not present. This assay takes approximately 20 minutes and should be performed on freshly reconstituted material.

Third-Party Independent Verification

For studies intended for publication, particularly those where GSH concentration is a primary experimental variable, sending a portion of the supplied material to a third-party analytical laboratory for independent HPLC-MS analysis is advisable. Services including Shimadzu Analytical Services, Intertek, and academic core facilities routinely offer small-molecule purity testing by HPLC and LC-MS/MS. The cost of a single sample analysis ($50-150 in most facilities) is negligible relative to the time invested in a multi-month animal study. Our supplier evaluation guide covers how to assess CoA documentation across vendors and what to look for in independent verification reports.

Stability Monitoring

Given the susceptibility of the free thiol to oxidation, a practical quality control step for research laboratories maintaining a stock vial over multiple months is periodic Ellman's assay verification. A stock vial stored at -20°C and opened under nitrogen flush every 3-4 months should maintain free thiol content within 5% of initial measurement. Progressive decline in Ellman's assay signal without change in total weight indicates conversion of GSH to GSSG and signals that the material should be replaced or that GSSG-specific experiments are appropriate rather than GSH-specific protocols.

Dosage and Reconstitution

Reconstitution Procedure

Glutathione dissolves readily in water at room temperature. The recommended reconstitution approach for general laboratory use is addition of sterile water for injection (WFI), phosphate-buffered saline (PBS, pH 7.4), or HEPES buffer (pH 7.0-7.4) to the lyophilized powder. ^[2] Unlike many peptide research compounds that require cosolvent addition (DMSO, acetic acid), reduced glutathione at concentrations up to 50-100 mg/mL is freely water-soluble without cosolvent, which simplifies preparation and avoids solvent-related cytotoxicity confounds in cell culture experiments.

A critical consideration for reconstitution is dissolved oxygen content of the reconstitution vehicle. Atmospheric oxygen dissolved in water will oxidize GSH over time, converting it to GSSG and reducing the effective concentration of the reduced form. To minimize oxidation during reconstitution, researchers should degas the reconstitution buffer by sparging with nitrogen or argon for 10-15 minutes before use, perform reconstitution under nitrogen atmosphere if possible, and limit the contact time between the reconstituted solution and air. The addition of a small quantity (0.1 mM) of DTPA (diethylenetriaminepentaacetic acid, a metal chelator) to the reconstitution buffer further reduces trace-metal-catalyzed oxidation by chelating iron and copper contaminants. Our detailed peptide reconstitution guide provides a step-by-step protocol including degassing technique and aliquoting approach.

Worked Reconstitution Examples

Example 1: Cell Culture Stock Solution Target: 10 mM GSH stock for cell culture (for ferroptosis experiments requiring 0.1-5 mM final concentrations in 96-well plates). Calculation: Molecular weight = 307.32 g/mol. For 10 mM in 10 mL: mass required = 10 mmol/L x 0.01 L x 307.32 g/mol = 30.73 mg. Dissolve 30.73 mg of compound in 10 mL degassed PBS (pH 7.4). This uses 30.73 mg from the 600 mg vial, leaving 569.27 mg for subsequent experiments. Aliquot in 0.5 mL portions into amber 1.5 mL microcentrifuge tubes, snap-freeze in liquid nitrogen, and store at -80°C. Each aliquot is single-use after thawing to prevent repeated freeze-thaw oxidation.

Example 2: Rodent Intraperitoneal Dosing Solution Target: Literature-reported research dose of 200 mg/kg in 25-gram mice, administered in 0.1 mL injection volume. Calculation: Dose per mouse = 0.025 kg x 200 mg/kg = 5 mg per mouse. In 0.1 mL, required concentration = 5 mg / 0.1 mL = 50 mg/mL. For a group of 10 mice (with 10% overage): prepare 11 doses x 0.1 mL = 1.1 mL at 50 mg/mL. Mass required = 50 mg/mL x 1.1 mL = 55 mg. Dissolve 55 mg in 1.1 mL sterile saline or PBS. This leaves 545 mg for remaining experimental groups or additional studies. Prepare fresh on the day of dosing; do not pre-make and store reconstituted solutions at high concentrations for more than 24 hours.

Example 3: Organ Bath / Ex-Vivo Tissue Superfusion Target: 1 mM GSH in 50 mL Krebs-Henseleit buffer for cardiac tissue superfusion in an I/R model. Calculation: Mass required = 0.001 mol/L x 0.05 L x 307.32 g/mol = 0.01537 g = 15.37 mg. Dissolve 15.37 mg in 50 mL freshly prepared, oxygenated Krebs-Henseleit buffer. Note: standard Krebs-Henseleit is prepared with 95% O2 / 5% CO2 (carbogen) which will oxidize GSH rapidly. For GSH superfusion protocols, use the buffer within 15-20 minutes of preparation or switch to nitrogen-based gassing for the pre-treatment period. Alternatively, add GSH immediately before cannulation of the heart and minimize exposure time. For the dosage calculation approach in detail, see our dosage calculation guide.

Research Dose Ranges from the Literature

These ranges are compiled from published animal model literature and are provided to support accurate experimental design and replication. They are not dosing recommendations for any species outside of appropriately approved preclinical research protocols.

Side Effects and Safety

Observed Adverse Findings in Preclinical Research

In the extensive preclinical literature on glutathione administration in rodent models, serious adverse events at research-range doses are uncommon. The absence of a dedicated receptor for glutathione (its biological actions are primarily mediated through chemistry rather than receptor-ligand binding) means that receptor-mediated off-target effects are not a major concern in the way they are for peptides acting through specific receptor systems. ^[1] However, several safety-relevant considerations warrant attention in research design.

At very high intravenous doses in rodents (above 1,000 mg/kg), hypotension has been observed and attributed to nitric oxide (NO) production from GSH-dependent pathways. GSH can react with oxidized NO metabolites to generate S-nitrosoglutathione (GSNO), a potent vasodilator, and high circulating GSNO can produce transient blood pressure reduction in instrumented animals. ^[6] This is primarily a concern for instrumented cardiovascular physiology experiments and does not preclude use at standard research doses, but blood pressure monitoring in studies using the higher end of the dose range is prudent.

Paradoxical pro-oxidant effects of high-dose glutathione are noted in certain contexts. At millimolar concentrations in the presence of redox-active metal ions (Fe2+, Cu+), GSH can participate in Fenton-type reactions generating hydroxyl radicals. This is generally relevant only in cell-free biochemistry settings or in iron-overload disease models, not in normal physiological research conditions, but it underscores the importance of using metal-chelated buffers (DTPA-supplemented) for cell-free mechanistic experiments. ^[3]

In cell culture experiments, excessive extracellular GSH can paradoxically reduce intracellular GSH by competing with cystine uptake through system Xc- (the cystine/glutamate antiporter), because extracellular cysteine (released from GSH catabolism by ectoenzymes) generates cysteine which can inhibit Xc- via product inhibition. This crosstalk means that dose-response curves for exogenous GSH in culture are not always monotonic, and pilot concentration-response experiments are advisable before large-scale studies.

Handling and Laboratory Safety

Reduced glutathione in powder form is classified as a low-hazard compound under standard laboratory safety frameworks. Standard PPE (gloves, eye protection, lab coat) is appropriate. The compound is not volatile, not flammable, and does not require special ventilation in most laboratory settings. Disposal follows standard non-hazardous laboratory waste procedures in most jurisdictions, but researchers should verify local regulations. Reconstituted solutions at high concentrations should be handled under standard biological safety protocols if prepared in aseptic conditions.

How It Compares

Glutathione occupies a specific niche in the redox biology and longevity research compound landscape. Several related compounds serve overlapping but distinct mechanistic roles and are frequently used in combination or as comparators with GSH in study designs.

The key differentiator for free reduced glutathione relative to cell-permeable analogues like GSH-MEE or S-acetyl glutathione is specificity of mechanism. Cell-permeable GSH prodrugs rapidly elevate intracellular GSH, but they also introduce ester or acetyl groups that are cleaved by intracellular esterases, and the kinetics of intracellular conversion affect the experimental window. For extracellular enzyme kinetics experiments (studying GPx or GST activity in cell-free systems), or for establishing medium composition controls in culture where known concentrations of the actual reduced tripeptide are required, free GSH is the appropriate research tool. ^[6]

N-Acetylcysteine (NAC) is the most commonly used indirect GSH-raising agent and is appropriate when researchers want to stimulate endogenous synthesis rather than supply exogenous substrate directly. The distinction matters for mechanistic interpretation: if a NAC-treated condition differs from a GSH-treated condition in its outcome, this implicates pathways beyond simple GSH replenishment, such as direct NF-kB inhibition by NAC's free thiol, as potential contributors. ^[8]

Alpha-lipoic acid (ALA) serves as a cofactor that can regenerate multiple antioxidants including GSH and vitamin C and is frequently used in combination with GSH in longevity and mitochondrial protection studies. The mechanistic synergy between ALA and GSH is documented in hepatocyte models of oxidative stress, where combined treatment preserves mitochondrial function better than either agent alone. ^[11]

For mitochondria-targeted redox research, MitoQ offers mechanistic advantages over free GSH because its triphenylphosphonium cation drives mitochondrial accumulation to concentrations 100-1,000-fold above cytosolic levels, directly addressing the limited access of GSH to the mitochondrial matrix without the use of specialized carriers. Researchers should choose between these tools based on which compartment's redox status is the primary experimental question.

Where to Buy

Apollo Peptide Sciences is the vendor for the Glutathione 600mg vial reviewed in this article. The combination of high vial mass (600 mg), competitive pricing ($35.00, approximately $0.058 per mg), and lyophilized format optimized for stability makes this offering well positioned for high-volume research applications. As with all research peptide purchases, independent CoA verification (see the Purity and Verification section above) is recommended before incorporating a new lot into ongoing experiments.

For researchers seeking multiple antioxidant and longevity-category compounds for comparative studies, our supplier guide evaluates the major research peptide vendors on CoA transparency, shipping conditions, batch consistency, and customer service responsiveness. Because reduced glutathione's stability is particularly sensitive to shipping temperature, suppliers who ship on dry ice or with temperature-monitoring cards and who lyophilize their products (rather than shipping pre-dissolved) should be prioritized.

To see our full independent review of this specific product including lot-specific CoA analysis and comparative pricing history, visit the Glutathione 600mg product page.

The internal product page links to the Apollo Peptide Sciences affiliate purchase pathway. Best Peptides For You may receive a commission on purchases made through these links, which helps fund independent editorial content. See our disclosure policy for full details. Our editorial assessments are independent of commercial relationships.

FAQ